Rapt Therapeutics (RAPT) Competitors $27.03 +2.03 (+8.12%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$27.18 +0.15 (+0.54%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RAPT vs. GPCR, BHVN, STOK, ABCL, IMCR, VCEL, JANX, EWTX, RCUS, and HRMYShould you be buying Rapt Therapeutics stock or one of its competitors? The main competitors of Rapt Therapeutics include Structure Therapeutics (GPCR), Biohaven (BHVN), Stoke Therapeutics (STOK), AbCellera Biologics (ABCL), Immunocore (IMCR), Vericel (VCEL), Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), Arcus Biosciences (RCUS), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry. Rapt Therapeutics vs. Its Competitors Structure Therapeutics Biohaven Stoke Therapeutics AbCellera Biologics Immunocore Vericel Janux Therapeutics Edgewise Therapeutics Arcus Biosciences Harmony Biosciences Rapt Therapeutics (NASDAQ:RAPT) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk. Do analysts prefer RAPT or GPCR? Rapt Therapeutics currently has a consensus price target of $24.78, indicating a potential downside of 8.33%. Structure Therapeutics has a consensus price target of $68.67, indicating a potential upside of 134.92%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Rapt Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rapt Therapeutics 1 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.58Structure Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Is RAPT or GPCR more profitable? Structure Therapeutics' return on equity of -21.31% beat Rapt Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rapt TherapeuticsN/A -67.92% -59.59% Structure Therapeutics N/A -21.31%-20.34% Which has higher earnings and valuation, RAPT or GPCR? Structure Therapeutics has lower revenue, but higher earnings than Rapt Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Rapt Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRapt Therapeutics$1.53M292.21-$129.87M-$14.17-1.91Structure TherapeuticsN/AN/A-$122.53M-$1.05-27.84 Does the media refer more to RAPT or GPCR? In the previous week, Rapt Therapeutics had 5 more articles in the media than Structure Therapeutics. MarketBeat recorded 12 mentions for Rapt Therapeutics and 7 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.04 beat Rapt Therapeutics' score of 0.47 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapt Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Structure Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, RAPT or GPCR? Rapt Therapeutics has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.65, meaning that its stock price is 265% less volatile than the S&P 500. Do institutionals & insiders believe in RAPT or GPCR? 99.1% of Rapt Therapeutics shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 2.4% of Rapt Therapeutics shares are held by company insiders. Comparatively, 5.6% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryStructure Therapeutics beats Rapt Therapeutics on 9 of the 15 factors compared between the two stocks. Get Rapt Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RAPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPT vs. The Competition Export to ExcelMetricRapt TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$413.45M$3.36B$6.11B$10.45BDividend YieldN/A2.30%5.73%4.77%P/E Ratio-1.9122.7785.4027.36Price / Sales292.21483.38599.20137.65Price / CashN/A46.7037.4661.86Price / Book2.3510.5512.446.81Net Income-$129.87M-$52.58M$3.32B$276.80M7 Day Performance-9.93%0.09%0.60%0.42%1 Month Performance53.32%15.61%10.53%7.86%1 Year Performance93.07%15.13%73.12%41.24% Rapt Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPTRapt Therapeutics3.3674 of 5 stars$27.03+8.1%$24.78-8.3%+86.7%$413.45M$1.53M-1.9180Analyst ForecastAnalyst RevisionGPCRStructure Therapeutics3.2147 of 5 stars$30.19+0.4%$68.67+127.4%-19.5%$1.73BN/A-28.75136Positive NewsBHVNBiohaven2.9859 of 5 stars$15.29-3.3%$48.85+219.6%-65.7%$1.67BN/A-2.00239STOKStoke Therapeutics3.0268 of 5 stars$30.34+0.5%$27.43-9.6%+180.5%$1.65B$36.56M35.69100Analyst ForecastABCLAbCellera Biologics2.2584 of 5 stars$5.67+2.5%$8.00+41.1%+138.3%$1.65B$28.83M-10.31500Gap UpIMCRImmunocore2.3061 of 5 stars$32.35-0.2%$56.89+75.9%+6.4%$1.63B$310.20M-80.88320VCELVericel3.1118 of 5 stars$33.49+5.1%$60.40+80.4%-19.9%$1.61B$237.22M279.11300News CoverageAnalyst ForecastAnalyst RevisionJANXJanux Therapeutics2.1364 of 5 stars$26.29-0.8%$78.31+197.9%-46.4%$1.59B$10.59M-14.6130EWTXEdgewise Therapeutics2.6658 of 5 stars$14.71-2.6%$38.83+164.0%-52.7%$1.59BN/A-9.4960RCUSArcus Biosciences1.9913 of 5 stars$16.64+14.0%$26.78+61.0%-5.2%$1.55B$258M-5.25500Analyst ForecastGap UpHRMYHarmony Biosciences4.7095 of 5 stars$26.36-0.7%$46.11+74.9%-25.0%$1.53B$714.73M8.50200Analyst Forecast Related Companies and Tools Related Companies Structure Therapeutics Competitors Biohaven Competitors Stoke Therapeutics Competitors AbCellera Biologics Competitors Immunocore Competitors Vericel Competitors Janux Therapeutics Competitors Edgewise Therapeutics Competitors Arcus Biosciences Competitors Harmony Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RAPT) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredBuy this stock before Tesla’s November 6 announcementThe End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapt Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapt Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
